0000000001311496

AUTHOR

Silvia Ventura

showing 23 related works from this author

Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction.

2016

Abstract Background Comorbid elderly patients with non-ST-elevation myocardial infarction (non-STEMI) are underrepresented in randomized trials and undergo fewer cardiac catheterizations according to registries. Our aim was to compare the conservative and invasive strategies in these patients. Methods Randomized multicenter study, including 106 patients (January 2012–March 2014) with non-STEMI, over 70 years and with comorbidities defined by at least two of the following: peripheral artery disease, cerebral vascular disease, dementia, chronic pulmonary disease, chronic renal failure or anemia. Patients were randomized to invasive (routine coronary angiogram, n = 52) or conservative (coronar…

Malemedicine.medical_specialtyCardiac Catheterizationmedicine.medical_treatmentComorbidityKaplan-Meier Estimate030204 cardiovascular system & hematologyRevascularizationCoronary Angiography03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicineMedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesRegistriesAngioplasty Balloon CoronaryProspective cohort studyNon-ST Elevated Myocardial InfarctionCardiac catheterizationAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelCardiovascular Agentsmedicine.diseaseComorbidityTreatment OutcomeSpainHeart failureCardiovascular agentCardiologyFemalebusinessEuropean journal of internal medicine
researchProduct

Serum Heat Shock Proteins as a Novel Biomarker for Heart Failure and Cardiovascular Diseases

2014

business.industryHeat shock proteinHeart failureCancer researchBiomarker (medicine)Medicinebusinessmedicine.disease
researchProduct

Green light-emitting electrochemical cells based on platinum(ii) complexes with a carbazole-appended carbene ligand

2022

This article is part of the themed collections: Paul R. Raithby at 70: in celebration of a life in chemistry, Recent Open Access Articles and 2022 Journal of Materials Chemistry C Most Popular Articles.

ElectroquímicaMaterials ChemistryGeneral ChemistryMaterials
researchProduct

Early Spot Urinary Sodium and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction

2020

<b><i>Objective:</i></b> In acute heart failure (AHF), early assessment of spot urinary sodium (U<sub>Na</sub>) has emerged as a useful biomarker for risk stratification and monitoring. The objective of this study was to investigate (a) whether early spot U<sub>Na</sub> predicts 24-h diuretic efficiency and (b) the clinical factors associated with early spot U<sub>Na</sub> in patients with AHF and concomitant renal dysfunction (RD). <b><i>Methods:</i></b> This is a post hoc analysis of the IMPROVE-HF trial, in which 160 patients with AHF and RD (estimated glomerular filtrate rate [eGFR] <60 mL/min/1…

medicine.medical_specialtymedicine.drug_classUrologymedicine.medical_treatmentUrologyInterquartile rangePost-hoc analysismedicineNatriuretic peptideHumansDiureticsAgedAged 80 and overHeart Failurebusiness.industrySodiumFurosemidemedicine.diseaseHeart failureConcomitantAcute DiseasePopulation studyKidney DiseasesDiureticCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiorenal Medicine
researchProduct

Frailty and other geriatric conditions for risk stratification of older patients with acute coronary syndrome

2014

Background Geriatric conditions may predict outcomes beyond age and standard risk factors. Our aim was to investigate a wide spectrum of geriatric conditions in survivors after an acute coronary syndrome. Methods A total of 342 patients older than 65 years were included. At hospital discharge, 5 geriatric conditions were evaluated: frailty (Fried and Green scores), physical disability (Barthel index), instrumental disability (Lawton-Brody scale), cognitive impairment (Pfeiffer questionnaire), and comorbidity (Charlson and simple comorbidity indexes). The outcomes were postdischarge mortality and the composite of death/myocardial infarction during a 30-month median follow-up. Results Seventy…

MaleGerontologyAcute coronary syndromemedicine.medical_specialtyFrail ElderlyMyocardial InfarctionComorbidityRisk AssessmentCohort StudiesRisk FactorsInternal medicineActivities of Daily LivingmedicineHumansProspective StudiesMyocardial infarctionAcute Coronary SyndromeGeriatric AssessmentAgedProportional Hazards ModelsAged 80 and overHand StrengthReceiver operating characteristicProportional hazards modelbusiness.industryHazard ratioPrognosismedicine.diseaseComorbidityROC CurveArea Under CurveMultivariate AnalysisExercise TestFemaleCognition DisordersCardiology and Cardiovascular MedicineRisk assessmentbusinessCohort studyAmerican Heart Journal
researchProduct

Expert system for predicting unstable angina based on Bayesian networks

2013

The use of computer-based clinical decision support (CDS) tools is growing significantly in recent years. These tools help reduce waiting lists, minimise patient risks and, at the same time, optimise the cost health resources. In this paper, we present a CDS application that predicts the probability of having unstable angina based on clinical data. Due to the characteristics of the variables (mostly binary) a Bayesian network model was chosen to support the system. Bayesian-network model was constructed using a population of 1164 patients, and subsequently was validated with a population of 103 patients. The validation results, with a negative predictive value (NPV) of 91%, demonstrate its …

education.field_of_studyUnstable anginaComputer sciencebusiness.industryPopulationGeneral EngineeringBayesian networkcomputer.software_genremedicine.diseaseClinical decision support systemExpert systemComputer Science ApplicationsArtificial IntelligencemedicineWeb applicationData miningeducationbusinesscomputerExpert Systems with Applications
researchProduct

Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

2017

Abstract Introduction and objectives The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1. Methods Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4 mg/dL on admission will be randomized to: a) standard diuretic str…

medicine.medical_specialtymedicine.medical_treatmentWater-Electrolyte ImbalanceRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyPatient Care Planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFurosemideInternal medicineHumansMedicine030212 general & internal medicineDiureticsIntensive care medicineHeart FailureCreatinineCardio-Renal Syndromebusiness.industryClinical study designChlorthalidoneMembrane ProteinsGeneral Medicinemedicine.diseasePathophysiologyAcetazolamideClinical trialchemistryCA-125 AntigenCreatinineHeart failureAcute DiseaseCardiologyDiureticbusinessRevista Española de Cardiología (English Edition)
researchProduct

Differential Effect of Glycosylated Hemoglobin Value and Antidiabetic Treatment on the Risk of 30-day Readmission Following a Hospitalization for Acu…

2015

In patients with heart failure and type 2 diabetes, low glycosylated hemoglobin has been related with higher risk of mortality but information regarding morbidity is scarce. We sought to evaluate the association between glycosylated hemoglobin and 30-day readmission in patients with type 2 diabetes and acute heart failure.Glycosylated hemoglobin was measured before discharge in 835 consecutive patients with acute heart failure and type 2 diabetes. Cox regression analysis adapted for competing events was used.Mean (standard deviation) age was 72.9 (9.6) years and median glycosylated hemoglobin was 7.2% (6.5%-8.0%). Patients treated with insulin or insulin/sulfonylurea/meglitinides were 41.1%…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentType 2 diabetesGastroenterologyPatient ReadmissionRisk AssessmentInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsAgedRetrospective StudiesGlycated HemoglobinHeart FailureProportional hazards modelbusiness.industryInsulinHazard ratioGeneral Medicinemedicine.diseasePrognosisSulfonylureaConfidence intervalPatient DischargeSurvival RateEndocrinologyDiabetes Mellitus Type 2SpainHeart failureAcute DiseaseFemalebusinessFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Vasodilator Stress CMR and All-Cause Mortality in Stable Ischemic Heart Disease

2020

Abstract Objectives This study explored the association of ischemic burden, as measured by vasodilator stress cardiovascular magnetic resonance (CMR), with all-cause mortality and the effect of revascularization on all-cause mortality in patients with stable ischemic heart disease (SIHD). Background In patients with SIHD, the association of ischemic burden, derived from vasodilator stress CMR, with all-cause mortality and its role for decision-making is unclear. Methods The registry consisted of 6,389 consecutive patients (mean age: 65 ± 12 years; 38% women) who underwent vasodilator stress CMR for known or suspected SIHD. The ischemic burden (at stress first-pass perfusion imaging) was com…

medicine.medical_specialtyVasodilator stressmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentHazard ratioIschemiaMagnetic resonance imagingPerfusion scanningDisease030204 cardiovascular system & hematologyRevascularizationmedicine.diseaseConfidence interval030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineInternal medicinemedicineCardiologyRadiology Nuclear Medicine and imagingCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Imaging
researchProduct

Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization …

2012

Recent observations in chronic stable heart failure suggest that high-dose loop diuretics (HDLDs) have detrimental prognostic effects in patients with high blood urea nitrogen (BUN), but recent findings have also indicated that diure- tics may improve renal function. Carbohydrate antigen 125 (CA125) has been shown to be a surrogate of systemic congestion. We sought to explore whether BUN and CA125 modulate the mortality risk associated with HDLDs following a hospitalization for acute heart failure (AHF). Methods and results We analysed 1389 consecutive patients discharged for AHF. CA125 and BUN were measured at a mean of 72+12 h after admission. HDLDs (≥120 mg/day in furosemide equivalent d…

Malemedicine.medical_specialtymedicine.drug_classRenal functionGastroenterologyRisk AssessmentLoop diureticsBlood Urea NitrogenCohort StudiesSodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinemedicineHumansProspective StudiesMortalityProspective cohort studyBlood urea nitrogenAgedAged 80 and overHeart Failurebusiness.industryHazard ratioFurosemideAcute heart failureLoop diureticMiddle Agedmedicine.diseaseConfidence intervalfemale genital diseases and pregnancy complicationsHospitalizationBlood urea nitrogenEndocrinologyCarbohydrate antigen 125Heart failureCA-125 AntigenAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesEuropean journal of heart failure
researchProduct

Estrategias diuréticas en insuficiencia cardiaca aguda con disfunción renal: terapia convencional frente a guiada por el antígeno carbohidrato 125. D…

2017

Resumen Introduccion y objetivos El tratamiento optimo de pacientes con insuficiencia cardiaca aguda (ICA) y sindrome cardiorrenal tipo 1 (SCR-1) no esta bien definido. La hipoperfusion arterial y la congestion venosa tienen un papel fundamental en la fisiopatologia del SCR-1. El antigeno carbohidrato 125 (CA125) ha emergido como marcador indirecto de sobrecarga de volumen en la ICA. El objetivo de este estudio es evaluar la utilidad del CA125 para el ajuste del tratamiento diuretico de pacientes con SCR-1. Metodos Ensayo clinico multicentrico, abierto y paralelo, que incluye a pacientes con ICA y creatinina ≥ 1,4 mg/dl al ingreso, aleatorizados a: a)  estrategia convencional: titulacion ba…

03 medical and health sciences0302 clinical medicinebusiness.industryMedicine030212 general & internal medicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Soluble ST2 and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction

2021

Abstract Background Identifying patients at risk of poor diuretic response in acute heart failure (AHF) is critical to make prompt adjustments in therapy. The objective of this study was to investigate whether the circulating levels of soluble ST2 predict the cumulative diuretic efficiency (DE) at 24 and 72 hours in patients with AHF and concomitant renal dysfunction. Methods and Results This is a post hoc analysis of the IMPROVE-HF trial, in which we enrolled 160 patients with AHF and renal dysfunction (estimated glomerular filtrate rate of Conclusions In patients with AHF and renal dysfunction at presentation, circulating levels of sST2 were independently and negatively associated with a …

Heart Failuremedicine.medical_specialtybusiness.industrymedicine.medical_treatment030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineFurosemideNegatively associatedInternal medicineConcomitantHeart failureAcute DiseasePost-hoc analysisCardiologyHumansMedicineKidney DiseasesIn patient030212 general & internal medicineDiureticDiureticsCardiology and Cardiovascular MedicinebusinessJournal of Cardiac Failure
researchProduct

Efecto diferencial de la glucohemoglobina y el tratamiento antidiabético sobre el riesgo de reingreso a 30 días después de un ingreso por insuficienc…

2015

Introduccion y objetivos En los pacientes con insuficiencia cardiaca y diabetes tipo 2, las cifras bajas de glucohemoglobina se han relacionado con un riesgo mas elevado de mortalidad, pero la informacion relativa a la morbilidad es escasa. El objetivo de este estudio fue evaluar la asociacion existente entre la glucohemoglobina y el reingreso en un plazo de 30 dias en los pacientes con diabetes tipo 2 e insuficiencia cardiaca aguda. Metodos Se determino la glucohemoglobina antes del alta en 835 pacientes consecutivos con insuficiencia cardiaca aguda y diabetes tipo 2. Se utilizo un analisis de regresion de Cox adaptado para eventos competitivos. Resultados La media de edad fue de 72,9 ± 9,…

business.industryMedicineCardiology and Cardiovascular MedicinebusinessHumanitiesRevista Española de Cardiología
researchProduct

Antigen carbohydrate 125 and creatinine on admission for prediction of renal function response following loop diuretic administration in acute heart …

2014

The use of loop diuretics in acute heart failure (AHF) is largely empirical and has been associated with renal function impairment by reducing renal perfusion but also renal improvement by decreasing renal venous congestion. Antigen carbohydrate 125 (CA125) has emerged as a proxy for fluid overload. We sought to evaluate whether the early changes in creatinine (ΔCr) induced by intravenous furosemide doses (ivFD) differ among clinical groups defined by overload status (CA125) and creatinine on admission (Cr).We included 526 consecutive patients admitted for AHF. All patients received intravenous furosemide for the first 48 hours. CA125 and Cr were dichotomized at 35 U/ml and 1.4 mg/dl, respe…

Malemedicine.medical_specialtymedicine.drug_classUrologyRenal functionKidneyCohort Studieschemistry.chemical_compoundPatient AdmissionAntigenSodium Potassium Chloride Symporter InhibitorsPredictive Value of TestsInternal medicinemedicineHumansIn patientInfusions IntravenousAgedAged 80 and overHeart FailureCreatininebusiness.industryFurosemideCarbohydrateLoop diureticMiddle Agedmedicine.diseaseEndocrinologychemistryHeart failureCA-125 AntigenCreatinineAcute DiseaseFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugFollow-Up StudiesInternational journal of cardiology
researchProduct

Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction.

2021

Introduction and objectives: Urinary sodium (UNa+) has emerged as a useful biomarker of poor clinical outcomes in acute heart failure (AHF). Here, we sought to evaluate: a) the usefulness of a single early determination of UNa+ for predicting adverse outcomes in patients with AHF and renal dysfunction, and b) whether the change in UNa+ at 24 hours (Delta UNa24 h) adds any additional prognostic information over baseline values. Methods: This is a post-hoc analysis of a multicenter, open-label, randomized clinical trial (IMPROVE-HF) (ClinicalTrials.gov NCT02643147) that randomized 160 patients with AHF and renal dysfunction on admission to a) the standard diuretic strategy, or b) a carbohydra…

medicine.medical_specialtyRenal failureTratamiento diuréticoAntígeno carbohidrato 125medicine.medical_treatmentRenal function030204 cardiovascular system & hematologyInsuficiencia cardiaca agudaGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInterquartile rangeInternal medicineBiomarker-guided therapyEnsayo clínicoTerapia guiada por biomarcadoresClinical endpointHumansMedicineDiureticsAgedAged 80 and overHeart Failurebusiness.industryFallo renalSodiumAcute heart failureGeneral Medicinemedicine.diseaseClinical trialClinical trialAcute heart failure Antígeno carbohidrato 125 Biomarker-guided therapy Carbohydrate antigen 125 Clinical trial Diuretic treatment Ensayo clínico Fallo renal Insuficiencia cardiaca aguda Renal failure Terapia guiada por biomarcadores Tratamiento diuréticoCarbohydrate antigen 125Heart failureAcute DiseaseDiuretic treatmentBiomarker (medicine)Kidney DiseasesDiureticbusiness
researchProduct

Indicaciones actuales de revascularización

2012

Randomized controlled trials in patients with chronic ischemic heart disease and stable angina indicate that the majority of cases can be managed by optimum medical treatment. The exceptions are patients with conditions that could benefit from revascularization, such as recurrent angina, extensive inducible ischemia or complex coronary anatomy. However, since studies have traditionally excluded patients with significant comorbidity, it is not clear which treatment approach would be best in these circumstances. Although patients with comorbidities are usually treated conservatively in routine clinical practice, some recent studies in elderly patients have raised the possibility that this sub…

medicine.medical_specialtyMedical treatmentbusiness.industrymedicine.medical_treatmentCoronary anatomyRevascularizationmedicine.diseaseComorbiditylaw.inventionAnginaRandomized controlled triallawInternal medicineCardiologymedicineInducible ischemiaIn patientCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología Suplementos
researchProduct

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

2020

BACKGROUND: The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal function in patients with acute heart failure and renal dysfunction at presentation. METHODS: This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-gui…

Maleendocrine system diseasesPREDICTIONmedicine.medical_treatmentUrine030204 cardiovascular system & hematologyKidney Function TestsCONGESTIONBiomarker guided-therapy0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsFurosemideNatriuretic peptideMedicineRenal Insufficiency030212 general & internal medicinePrecision MedicineANTIGEN CARBOHYDRATE 125Aged 80 and overFurosemideGeneral MedicineDiuretic treatmentEUROPEAN-SOCIETYClinical trialFemaleTRIALmedicine.drugmedicine.medical_specialtyRenal failureSTRATEGIESmedicine.drug_classUrologyRenal function03 medical and health sciencesHumansIn patientAgedHeart FailureSERUM CREATININENATRIURETIC PEPTIDEbusiness.industryMORTALITYMembrane ProteinsAcute heart failuremedicine.diseaseClinical trialCarbohydrate antigen 125CA-125 AntigenHeart failureDiuretic treatmentDiureticbusinessCARDIORENAL SYNDROME
researchProduct

Differential Prognostic Effect of Revascularization According to a Simple Comorbidity Index in High-Risk Non-ST-Segment Elevation Acute Coronary Synd…

2011

Background: Data on the effect of revascularization on outcome in patients with high-risk non–ST-segment elevation acute coronary syndrome (NSTEACS) and significant comorbidities are scarce. Recently, a simple comorbidity index (SCI) including 5 comorbidities (renal failure, dementia, peripheral artery disease, heart failure, and prior myocardial infarction [MI]) has shown to be a useful tool for risk stratification. Nevertheless, therapeutic implications have not been derived. Hypothesis: We sought to evaluate the prognostic effect attributable to revascularization in NSTEACS according the SCI score. Methods: We included 1017 consecutive patients with NSTEACS. The effect of revascularizati…

Malemedicine.medical_specialtyAcute coronary syndromeTime Factorsmedicine.medical_treatmentDecision MakingStatistics as TopicClinical InvestigationsComorbidityKaplan-Meier EstimateRevascularizationRisk AssessmentInterquartile rangeInternal medicineConfidence IntervalsmedicineHealth Status IndicatorsHumansST segmentProspective StudiesMyocardial infarctionAcute Coronary SyndromePropensity ScoreAgedProportional Hazards Modelsbusiness.industryProportional hazards modelHazard ratioGeneral MedicineMiddle AgedPrognosismedicine.diseaseTroponinConfidence intervalSurgerySpainCardiologyFemaleCardiology and Cardiovascular MedicinebusinessClinical Cardiology
researchProduct

Trayectoria precoz del sodio urinario y riesgo de eventos adversos en insuficiencia cardiaca aguda y disfunción renal

2021

Resumen Introduccion y objetivos El sodio urinario (UNa+) ha surgido como un biomarcador util para predecir eventos clinicos desfavorables en pacientes con insuficiencia cardiaca aguda (ICA). En este estudio pretendemos evaluar: a) la utilidad de una unica determinacion precoz de UNa+ para predecir eventos adversos en pacientes con ICA e insuficiencia renal (IR) concomitante, y b) si los cambios en el UNa+ a las 24 horas (ΔUNa24 h) anaden informacion pronostica adicional sobre los valores basales. Metodos Analisis post-hoc del ensayo clinico multicentrico, abierto y paralelo (IMPROVE-HF), (ClinicalTrials.gov NCT02643147) en el que 160 pacientes con ICA e IR concomitante al ingreso fueron al…

Gynecology03 medical and health sciencesmedicine.medical_specialty0302 clinical medicinebusiness.industrymedicine030204 cardiovascular system & hematologyCardiology and Cardiovascular MedicinebusinessRevista Española de Cardiología
researchProduct

CCDC 2151291: Experimental Crystal Structure Determination

2022

Related Article: Sara Fuertes, Lorenzo Mardegan, Ignacio Martínez, Silvia Ventura, Irene Ara, Daniel Tordera, Henk J. Bolink, Violeta Sicilia|2022|J.Mater.Chem.C|10|15491|doi:10.1039/D2TC02539F

Space GroupCrystallographyCrystal System(2-(3-methylimidazol-2-ylidene-1-yl)-5-(9H-carbazol-9-yl)phenyl)-(2-[2-(diphenylphosphino)ethyl]pyridine)-platinum hexafluorophosphate dichloromethane solvateCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2151293: Experimental Crystal Structure Determination

2022

Related Article: Sara Fuertes, Lorenzo Mardegan, Ignacio Martínez, Silvia Ventura, Irene Ara, Daniel Tordera, Henk J. Bolink, Violeta Sicilia|2022|J.Mater.Chem.C|10|15491|doi:10.1039/D2TC02539F

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(2-(3-methylimidazol-2-ylidene-1-yl)-5-(9H-carbazol-9-yl)phenyl)-(12-phenylenebis(diphenylphosphine))-platinum hexafluorophosphate n-pentane solvateExperimental 3D Coordinates
researchProduct

CCDC 2151294: Experimental Crystal Structure Determination

2022

Related Article: Sara Fuertes, Lorenzo Mardegan, Ignacio Martínez, Silvia Ventura, Irene Ara, Daniel Tordera, Henk J. Bolink, Violeta Sicilia|2022|J.Mater.Chem.C|10|15491|doi:10.1039/D2TC02539F

Space GroupCrystallographyCrystal SystemCrystal StructureCell Parameters(2-(3-methylimidazol-2-ylidene-1-yl)-5-(9H-carbazol-9-yl)phenyl)-pyridine-(triphenylphosphine)-platinum hexafluorophosphate dichloromethane solvateExperimental 3D Coordinates
researchProduct

CCDC 2151292: Experimental Crystal Structure Determination

2022

Related Article: Sara Fuertes, Lorenzo Mardegan, Ignacio Martínez, Silvia Ventura, Irene Ara, Daniel Tordera, Henk J. Bolink, Violeta Sicilia|2022|J.Mater.Chem.C|10|15491|doi:10.1039/D2TC02539F

Space GroupCrystallography(methylenebis(diphenylphosphine))-(2-(3-methylimidazol-2-ylidene-1-yl)-5-(9H-carbazol-9-yl)phenyl)-platinum hexafluorophosphate dichloromethane solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct